VTR · Ventas, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.83B | $4.92B | $4.50B | $4.13B | $3.83B | $3.80B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $177.40M | $162.99M | $148.88M | $144.87M | $129.76M | $130.16M |
| Total Operating Expenses | $5.63B | $4.93B | $4.61B | $4.22B | $3.99B | $3.71B |
| D&A | $1.38B | $1.25B | $1.39B | $1.20B | $1.20B | $1.11B |
| Operating Income | $204.32M | ($8.00M) | ($115.58M) | $80.59M | ($162.38M) | $80.59M |
| Interest Expense | $612.25M | $602.84M | $574.11M | $467.56M | $440.09M | $469.54M |
| Income Tax | ($14.15M) | ($37.77M) | ($9.54M) | ($16.93M) | $4.83M | ($96.53M) |
| Net Income | $251.38M | $81.15M | ($40.97M) | ($47.45M) | $49.01M | $439.15M |
| EPS - Basic | $0.55 | $0.20 | ($0.10) | ($0.12) | $0.13 | $1.18 |
| EPS - Diluted | $0.54 | $0.19 | ($0.10) | ($0.12) | $0.13 | $1.17 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $741.07M | $897.85M | $508.79M | $122.56M | $149.72M | $413.33M |
| Accounts Receivable | $99.87M | $108.14M | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | - | - | - | - | - | - |
| Total Assets | $27.59B | $26.19B | $24.73B | $24.16B | $24.72B | $23.93B |
| Current Liabilities | - | - | - | - | - | - |
| Long-term Debt | $13.01B | $13.52B | $13.49B | $12.30B | $12.03B | $11.90B |
| Total Liabilities | $14.63B | $15.05B | $14.88B | $13.67B | $13.49B | $13.42B |
| Stockholders' Equity | $12.53B | $10.77B | $9.49B | $10.15B | $10.85B | $10.18B |
| Retained Earnings | ($7.53B) | ($6.89B) | ($6.21B) | ($5.45B) | ($4.68B) | ($4.03B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.65B | $1.33B | $1.12B | $1.12B | $1.03B | $1.45B |
| Investing Cash Flow | ($2.69B) | ($2.38B) | ($184.66M) | ($859.22M) | ($724.14M) | $154.29M |
| Financing Cash Flow | $873.76M | $1.45B | ($543.75M) | ($283.93M) | ($558.47M) | ($1.30B) |
| CapEx | $2.93B | $2.53B | $649.47M | $900.70M | $1.80B | $607.30M |
| Free Cash Flow | ($1.28B) | ($1.20B) | $470.40M | $219.47M | ($775.90M) | $842.88M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 3.5% | -0.2% | -2.6% | 2.0% | -4.2% | 2.1% |
| EBITDA margin | 27.1% | 25.3% | 28.4% | 31.0% | 27.0% | 31.4% |
| Net margin | 4.3% | 1.6% | -0.9% | -1.1% | 1.3% | 11.6% |
| Free cash flow margin | -22.0% | -24.4% | 10.5% | 5.3% | -20.3% | 22.2% |
| FCF / Net income | -5.10 | -14.79 | -11.48 | -4.63 | -15.83 | 1.92 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 3.0% | 3.3% | 3.3% | 3.5% | 3.4% | 3.4% |
| Effective tax rate | -6.0% | -87.1% | - | - | 9.0% | -28.2% |
| Return on assets | 0.9% | 0.3% | -0.2% | -0.2% | 0.2% | 1.8% |
| Return on equity | 2.0% | 0.8% | -0.4% | -0.5% | 0.5% | 4.3% |
| Return on invested capital | 0.8% | -0.0% | -0.4% | 0.3% | -0.6% | 0.4% |
| Liquidity | ||||||
| Current ratio | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - |
| Leverage | ||||||
| Debt / Equity | 1.04 | 1.26 | 1.42 | 1.21 | 1.11 | 1.17 |
| Debt / Assets | 0.47 | 0.52 | 0.55 | 0.51 | 0.49 | 0.50 |
| Debt / EBITDA | 8.22 | 10.86 | 10.57 | 9.62 | 11.62 | 9.99 |
| Interest coverage | 0.3x | -0.0x | -0.2x | 0.2x | -0.4x | 0.2x |
| Equity multiplier | 2.20 | 2.43 | 2.61 | 2.38 | 2.28 | 2.35 |
| Liabilities / Assets | 0.53 | 0.57 | 0.60 | 0.57 | 0.55 | 0.56 |
| Efficiency | ||||||
| Asset turnover | 0.21 | 0.19 | 0.18 | 0.17 | 0.15 | 0.16 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 6d | 8d | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 143.3x | 309.9x | - | - | 393.2x | 41.9x |
| P / B | 2.9x | 2.3x | 2.1x | 1.8x | 1.8x | 1.8x |
| P / S | 6.1x | 5.0x | 4.5x | 4.4x | 5.2x | 4.9x |
| EV / EBITDA | 30.4x | 29.8x | 26.0x | 23.7x | 30.6x | 25.2x |
| Growth | ||||||
| Revenue growth (YoY) | 18.5% | 9.5% | 8.9% | 7.9% | 0.9% | -2.0% |
| Revenue CAGR (3y) | 12.2% | 8.8% | 5.8% | 2.2% | 0.7% | 2.0% |
| Revenue CAGR (5y) | 9.0% | 4.9% | 3.7% | 2.9% | 2.1% | 2.9% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 93.1% | - | - | - | - |
| Net income growth (YoY) | 209.8% | - | 13.6% | - | -88.8% | 1.4% |
| EPS growth (YoY) | 184.2% | - | 16.7% | - | -88.9% | 0.0% |
| EPS CAGR (3y) | - | 13.5% | - | - | -51.5% | -32.4% |
| EPS CAGR (5y) | -14.3% | -30.5% | - | - | -41.3% | -1.3% |
| FCF growth (YoY) | -6.8% | - | 114.3% | - | - | -34.2% |
| FCF CAGR (5y) | - | - | -17.7% | -30.0% | - | -8.1% |
| Book value growth (YoY) | 16.3% | 13.5% | -6.5% | -6.5% | 6.6% | -2.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$5.78B totalSenior Living Operations$4.28B · 74.0%
Outpatient Medical And Research Portfolio$897.90M · 15.5%
Triple Net Leased Properties$601.58M · 10.4%
Product / service
$4.31B totalResident Feesand Services$4.28B · 99.2%
Third Party Capital Management$17.55M · 0.4%
Management Service$15.70M · 0.4%
Geographic
$5.83B totalUS$5.21B · 89.3%
CA$552.92M · 9.5%
GB$71.23M · 1.2%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- -Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing Ventas against the 5 most active filers in the same SIC group.
Dividends
$1.96/share trailing 12 months · +7.1% YoY
| Ex-date | Per share |
|---|---|
| Mar 31, 2026 | $0.5200 |
| Dec 31, 2025 | $0.4800 |
| Sep 30, 2025 | $0.4800 |
| Jun 30, 2025 | $0.4800 |
| Mar 31, 2025 | $0.4800 |
| Dec 31, 2024 | $0.4500 |
| Oct 1, 2024 | $0.4500 |
| Jul 1, 2024 | $0.4500 |
| Mar 28, 2024 | $0.4500 |
| Dec 29, 2023 | $0.4500 |
| Sep 29, 2023 | $0.4500 |
| Jun 30, 2023 | $0.4500 |
| Mar 31, 2023 | $0.4500 |
| Dec 30, 2022 | $0.4500 |
| Sep 30, 2022 | $0.4500 |
| Jun 30, 2022 | $0.4500 |
| Mar 31, 2022 | $0.4500 |
| Dec 31, 2021 | $0.4500 |
| Sep 30, 2021 | $0.4500 |
| Jun 30, 2021 | $0.4500 |
| Mar 31, 2021 | $0.4500 |
| Dec 31, 2020 | $0.4500 |
| Sep 30, 2020 | $0.4500 |
| Jun 30, 2020 | $0.4500 |